X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. It is being evaluated for the treatment of solid tumor in adults.
Lead Product(s): SYS6002
Therapeutic Area: Oncology Product Name: CRB-701
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
The net proceeds will be used for the clinical development of CRB-701, which is an antibody-drug conjugate that targets the expression of Nectin-4 on cancerous cells.
Lead Product(s): CRB-701
Therapeutic Area: Oncology Product Name: CRB-701
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $94.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2024
Details:
The net proceeds will be used for the clinical development of CRB-701, which is an antibody-drug conjugate that targets the expression of Nectin-4 on cancerous cells.
Lead Product(s): CRB-701
Therapeutic Area: Oncology Product Name: CRB-701
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $82.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 31, 2024
Details:
CRB-601 is a potentially best-in-class TGFβ blocking monoclonal antibody targeting the integrin αvβ8. It is being evaluated for the treatment of Alpha-v beta-8 enriched solid tumors.
Lead Product(s): CRB-601
Therapeutic Area: Oncology Product Name: CRB-601
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
CRB-601, a potentially best-in-class TGFβ blocking monoclonal antibody targeting the integrin αvβ8. It is being evaluated in IND-enabling studies for the treatment of solid tumors.
Lead Product(s): CRB-601
Therapeutic Area: Oncology Product Name: CRB-601
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
The agreement covers exclusive commercialization rights to CRB-701, a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: CRB-701
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Megalith Pharmaceuticals
Deal Size: $692.5 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement February 13, 2023
Details:
CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors in vivo.
Lead Product(s): CRB-601,Undisclosed
Therapeutic Area: Oncology Product Name: CRB-601
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
The latest preclinical data for CRB-601 demonstrate its significant effects on inhibiting tumor growth as a single agent and in combination with anti-PD-1 treatment in the MC38 and EMT6 syngeneic tumor models.
Lead Product(s): CRB-601,Undisclosed
Therapeutic Area: Oncology Product Name: CRB-601
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
In vitro preclinical data demonstrated high affinity of CRB-601 for αvb8 and resulting effect on TGFb, it also showed significant inhibition of tumor growth in a syngeneic model of colon cancer by CRB-601, both as a single agent and in combination with anti-PD-1 treatment.
Lead Product(s): CRB-601
Therapeutic Area: Oncology Product Name: CRB-601
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
At Week 28, the lenabasum 20 mg twice daily group achieved a mean TIS of 28.3 versus the control group mean TIS of 26.7, p = 0.1965. Lenabasum treatment was safe and well-tolerated in this study.
Lead Product(s): Lenabasum
Therapeutic Area: Immunology Product Name: JBT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
